# A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)

> **NCT01236430** · PHASE1 · COMPLETED · sponsor: **Organon and Co** · enrollment: 200 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Ezetimibe
- **DRUG:** Ezetimibe/atorvastatin 10mg/10mg FDC
- **DRUG:** Atorvastatin 10mg
- **DRUG:** Atorvastatin 80mg
- **DRUG:** Ezetimibe/atorvastatin 10mg/80mg FDC

## Key facts

- **NCT ID:** NCT01236430
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-11
- **Final completion:** 2012-02
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2022-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01236430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01236430, "A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01236430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*